{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2016"],"condition":["colorectal cancer"],"disease":["Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2638699"],"location":["Japan"],"study_start_month":["8"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"A phase II trial of lenvatinib in patients with metastatic colorectal cancer after standard chemotherapy  (NCCH1503,Lemon trial)","description":"Interventions: 24mg of lenvatinib is orally taken once daily.\nPrimary outcome(s): Disease control rate\nStudy Design: Single arm Non-randomized","dates":{"creation":"2016-08-15"},"accession":"2638699","cross_references":{"Japan Primary Registries Network":["JPRN-UMIN000023446"]}}